Please login to the form below

Not currently logged in
Email:
Password:

Amicus Therapeutics

This page shows the latest Amicus Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amicus forms gene therapy manufacturing partnership with Catalent

Amicus forms gene therapy manufacturing partnership with Catalent

Biotech invests to speed gene therapies into clinical trials. US biotech Amicus Therapeutics is to work with drug development services company Catalent Biologics to develop its cell and gene therapy manufacturing ... The agreement will also see the

Latest news

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    It was clearly a good news – bad news day for Amicus Therapeutics this month when two press releases were released. ... for Pompe disease. Amicus also announced plans to cut costs as part of a restructuring to focus on enzyme replacement therapies.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...